RxDoctor Payments Data

James Caskey, MD

Family Medicine · Lufkin, TXNPI 1558371880

Payments from drug & device makers

$1,089in general payments, 2019–2025

Across 85 payments — averaging $12.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$352
  • AstraZeneca$296
  • AbbVie$154
  • World Class Technology Corporation$84
  • Abbott$70
  • Exact Sciences$56
  • plus $77 from 4 others

What the payments were for

  • Food & beverage$1,089100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,089 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$216,787
Medicare patients
401
Services billed
4,338

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide89$119,826
JardianceEmpagliflozin63$69,296
EliquisApixaban72$66,570
XareltoRivaroxaban74$55,905
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog37$43,097
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$37,074
FarxigaDapagliflozin Propanediol41$31,821
MounjaroTirzepatide12$21,673
TrulicityDulaglutide20$19,899
Tresiba Flextouch U-200Insulin Degludec12$12,637
Janumet XrSitagliptin Phos/Metformin Hcl13$11,080
Synjardy XrEmpagliflozin/Metformin Hcl14$8,967
EvoxacCevimeline Hcl11$7,742
Repatha SureclickEvolocumab14$6,869
Levothyroxine Sodium485$5,868

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$15$119,82689 claims
PfizerEliquis$13$66,57072 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$16$43,70848 claims
AstraZenecaFarxiga$296$31,82141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Lufkin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →